HOPA 2018 | More focus is needed on subtypes of lung cancer that do not have FDA-approved targeted therapies

There are now four FDA approvals that have molecular-specific licenses for lung cancer, these include ALK rearrangements, EGFR mutations, BRAF V600E mutations and ROS1 rearrangements. Now, speaking at the Hematology/Oncology Pharmacy Association (HOPA) Annual Conference, held in Denver, CO, Ross Camidge, MD, PhD, of University of Colorado, Aurora, CO, discusses the abnormalities that do not have FDA-approved targted drugs and raises the interesting question of who is actually benefitting from the treatment options.